



September 24, 2026

Company Name: Japan Lifeline Co., Ltd.
 Representative: Keisuke Suzuki, President and CEO
 (Security Code: 7575; TSE Prime Market)
 Inquiries: Takeyoshi Egawa, Director and CFO
 (TEL. +81-3-6711-5200)

Japan Lifeline Announces Change in Specified Subsidiary Following Capital Increase in U.S. Subsidiary

TOKYO, JAPAN – September 24, 2026 – Japan Lifeline Co., Ltd. ("the Company") announced that its Board of Directors resolved today, via a written resolution pursuant to Article 370 of the Companies Act and the Company's Articles of Incorporation, to implement a capital increase for JLL Med USA Inc. ("JLL Med USA"), its consolidated subsidiary in the United States. Following this capital increase, JLL Med USA's capital will equal or exceed 10% of the Company's capital, making it a specified subsidiary of the Company. Details are as follows.

1. Reason for the Capital Increase

The Company has set "expansion of global sales" as one of its medium- to long-term growth strategies, and positions the United States, the world's largest medical device market, as its most important region. To build a business foundation in the U.S., the Company established JLL Med USA as a wholly owned subsidiary on August 25, 2026.

The purpose of this capital increase is to strengthen JLL Med USA's financial base, enabling it to develop its business in the U.S. market in an agile manner. JLL Med USA will build a development and sales structure capable of promptly responding to local medical needs, thereby contributing to the enhancement of the overall corporate value of the Group through the growth of the U.S. business.

2. Overview of the Specified Subsidiary

(1) Name	JLL Med USA Inc.
(2) Location	16802 Aston Street, Irvine, CA 92606, USA
(3) Representative	Nobuo Takahashi, President and Chief Executive Officer
(4) Business Description	Development and sales of medical devices
(5) Share Capital	USD 400,000
(6) Date of Establishment	August 25, 2026
(7) Major Shareholder and Ownership Ratio	Japan Lifeline Co., Ltd. / 100%

(8) Relationship Between the Company and the Subsidiary	Capital Relationship	The Company holds 100% of its shares.
	Personnel Relationship	Directors of the Company concurrently serve as directors of the subsidiary.
	Business Relationship	There is no business relationship to be disclosed at this time.

Note: As JLL Med USA was established on August 25, 2026, there are no financial figures available.

3. Overview of the Capital Increase

(1) Date of Decision	September 24, 2026
(2) Amount of Capital Increase	USD 10,000,000
(3) Capital After Capital Increase	USD 10,400,000
(4) Ownership Ratio After Capital Increase	100%

4. Impact on the Company's Financial Results

The impact on the Company's consolidated financial results for the fiscal year ending March 31, 2027 will be immaterial.